Overactive Bladder Clinical Trial
Official title:
The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse
Pelvic organ prolapse (POP) is a common condition in women. Approximately 20% of women
undergo surgical correction for POP in their lifetime. Overactive bladder symptoms (OAB) are
often associated with POP in 25-69% of patients and POP has been shown to be an independent
risk factor for OAB. There is scientific evidence that surgical repair of POP reduces or
eliminates OAB in >85%. In addition, stress urinary incontinence (SUI) is also often
associated with POP, either clinically evident or as a potential post-operative complication.
The clinical decision as to include a surgical technique to treat SUI when repairing POP
surgically is still a matter of controversy. Most surgeons at the institution will include an
extra procedure, specifically a retropubic sling, if SUI is clinically evident. Some will not
include it unless there is urodynamic or clinical evidence of potential SUI post-operatively.
Finally, some will include it regardless of clinical or urodynamic findings based on the
apparent high incidence of such SUI after prolapse repair. The Tension-Free-Vaginal Tape
(TVT) has been observed to reduce OAB as well as produce de-novo OAB symptoms, so the effect
of TVT on OAB is still unclear.
The purpose of this study is to determine the effect of additional TVT surgery on OAB
symptoms in patients undergoing POP repair. It is hoped that such data will better determine
the effect of either surgical intervention strategy on OAB symptoms. This is a prospective
cohort study comparing patients with OAB that undergo surgical repair of their prolapse with
or without additional TVT surgery. The outcomes will be measured using pre- and
post-operative validated questionnaires (PFDI-20, OAB-q short form).
Hypothesis: Based on the limited data available, the investigators expect to find that there
will be less improvement in OAB symptoms in women undergoing POP surgery with TVT than those
undergoing POP surgery alone.
Primary Aim: To determine what effect the addition of a TVT will have on OAB symptoms in
women undergoing surgical repair of pelvic organ prolapse using validated questionnaires.
Secondary Aims: To compare postoperative complications between those undergoing prolapse
surgery alone and those undergoing prolapse surgery and TVT. Lastly the investigators would
like to evaluate comorbidities and potential association to the degree of OAB symptoms
Methods:
Potential eligible subjects will be recruited using information provided by urogynecology
staff and by reviewing the upcoming OR schedule. After subjects have been identified, the
surgeon will be contacted to confirm whether or not their patient can be contacted by the
research team. Only after permission has been communicated from the surgeon to the research
team will the team approach the patient about potential participation.
After the patient is consented to participate she will be asked to fill out a PFDI-20
questionnaire. This is a validated questionnaire divided into 3 sections relating to prolapse
symptoms, bowel symptoms and urinary symptoms, respectively. It is based on a 5 point scale-
0 for no, and then in terms of how bothersome symptoms are 2- not at all, 3- somewhat, 4-
moderately, 5- quite a bit. A higher score indicates greater degree of bother. Focus will be
on the UDI-6 section, pertaining to urinary symptoms.
The questions that will determine inclusion or exclusion of the patients are questions 15 and
16: "Do you usually experience frequent urination" and "Do you usually experience urine
leakage associated with a feeling of urgency; that is, a strong sensation of needing to go to
the bathroom?" Those who respond negatively to these questions will be excluded and those who
respond affirmatively to both questions will be included.
The patients with OAB symptoms will be asked to fill out the OAB-q short form validated
questionnaire which includes a 6-item symptoms bother scale (OAB-q ss) and a 13-item HRQL
scale (OAB-q HRQL). This should be completed pre-operatively and then again 6 weeks, 6 months
and 12 months post-operatively.
Interventions: No interventions will be made. This is an observational study.
Outcomes Primary: The primary outcome will be measured using pre- and post-operative
validated questionnaires (PFDI-20, OAB-q short form). The primary study endpoint will be the
Overactive Bladder Questionnaire Symptom Severity (OAB-q ss) change score 6 weeks after
surgery. The change score is the score pre-operatively minus the score post-operatively. A
positive score indicates lesser symptoms severity after surgery. The investigators will
define a significant improvement to be a change score on the OAB-q ss≥10 based on previous
work that determined that the minimally important difference in the OAB-q ss is 10 or higher.
Secondary: The secondary study endpoints will be the OAB-q HRQL change score and the UDI-6
change score calculated using the same method above.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Completed |
NCT00910520 -
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
|
Phase 3 |